Shandong Weigao Group Medical Polymer Co Ltd Class H (HK:1066)
:1066
Want to see HK:1066 full AI Analyst Report?
Top Page
Shandong Weigao Group Medical Polymer Co
(1066)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$5.50
▼(-0.90% Downside)
Action:ReiteratedDate:10/14/25
The stock's overall score is primarily driven by its strong valuation, with an attractive P/E ratio and dividend yield. Financial performance is solid, but concerns about revenue decline and cash flow management slightly dampen the outlook. Technical analysis suggests weak market momentum, which is a risk factor.
Positive Factors
High Profitability
Sustained high gross and healthy net margins indicate durable pricing power and efficient cost structure in core polymer medical consumables. This profitability supports internal reinvestment, dividend capacity and resilience to cost shocks over the medium term.
Negative Factors
Slight Revenue Decline
A falling top line, even if modest, erodes operating leverage and constrains capacity to expand margins or invest in growth. If sustained, revenue decline could force margin trade-offs or limit the company's ability to scale R&D and commercial efforts over months.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Sustained high gross and healthy net margins indicate durable pricing power and efficient cost structure in core polymer medical consumables. This profitability supports internal reinvestment, dividend capacity and resilience to cost shocks over the medium term.
Read all positive factors
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$16.24B
Dividend Yield4.58%
Average Volume (3M)10.92M
Price to Earnings (P/E)13.0
Beta (1Y)1.09
Revenue Growth2.34%
EPS Growth-22.13%
CountryHK
Employees12,719
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.15
Shares Outstanding4,522,332,500
10 Day Avg. Volume7,849,305
30 Day Avg. Volume10,915,466
Financial Highlights & Ratios
PEG Ratio2.08
Price to Book (P/B)0.82
Price to Sales (P/S)1.49
P/FCF Ratio8.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.62Price Target Upside1.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.4
Revenue Forecast (FY)HK$14.25B
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Company Description
Shandong Weigao Group Medical Polymer Co., Ltd. is a leading Chinese manufacturer specializing in the production of medical devices and polymer products. Established in 1992, the company operates primarily in the healthcare sector, offering a dive...
How the Company Makes Money
Shandong Weigao Group generates revenue through the sale of its medical devices and consumables, which are essential for healthcare facilities. The company has established a comprehensive revenue model that includes direct sales to hospitals and h...
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.10B | 13.09B | 13.23B | 13.62B | 13.15B | 11.62B |
| Gross Profit | 6.46B | 6.58B | 6.64B | 7.31B | 7.35B | 6.46B |
| EBITDA | 3.08B | 3.14B | 3.55B | 4.38B | 3.75B | 3.09B |
| Net Income | 1.97B | 2.07B | 2.00B | 2.76B | 2.28B | 2.09B |
Balance Sheet | ||||||
| Total Assets | 36.14B | 34.76B | 33.67B | 33.20B | 30.37B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 9.65B | 8.32B | 7.33B | 7.49B | 7.13B | 6.14B |
| Total Debt | 5.51B | 4.19B | 4.17B | 4.49B | 4.14B | 4.32B |
| Total Liabilities | 10.45B | 9.42B | 9.68B | 9.75B | 9.46B | 8.95B |
| Stockholders Equity | 24.10B | 23.75B | 22.45B | 21.67B | 19.27B | 17.55B |
Cash Flow | ||||||
| Free Cash Flow | 2.05B | 2.19B | 2.11B | 1.10B | 1.92B | 1.70B |
| Operating Cash Flow | 2.65B | 2.79B | 2.80B | 2.21B | 3.04B | 2.70B |
| Investing Cash Flow | -2.21B | -1.10B | -1.39B | -2.57B | -1.48B | 423.22M |
| Financing Cash Flow | -500.93M | -1.60B | -2.16B | -1.02B | -547.92M | -1.79B |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Negative
5.55
Price Trends
4.66
Negative
4.99
Negative
5.50
Negative
Market Momentum
-0.32
Positive
28.42
Positive
28.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Negative. The current price of 5.55 is above the 20-day moving average (MA) of 4.05, above the 50-day MA of 4.66, and above the 200-day MA of 5.50, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 28.42 is Positive, neither overbought nor oversold. The STOCH value of 28.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1066.
Shandong Weigao Group Medical Polymer Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$5.68B | 8.36 | 16.76% | 3.65% | 11.07% | 48.01% | |
77 Outperform | HK$3.20B | 4.32 | 10.21% | 2.70% | 9.88% | 5.65% | |
74 Outperform | HK$1.77B | 19.04 | 3.68% | 7.46% | 7.11% | -34.66% | |
69 Neutral | HK$8.26B | 20.75 | 11.20% | ― | 25.24% | 7.29% | |
68 Neutral | HK$16.24B | 13.02 | 6.64% | 4.58% | 2.34% | -22.13% | |
66 Neutral | HK$15.34B | ― | 4.03% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1066
Shandong Weigao Group Medical Polymer Co
3.55
-1.92
-35.08%
HK:1358
PW Medtech Group Ltd.
1.12
0.17
17.89%
HK:3600
Modern Dental Group Limited
6.15
2.15
53.87%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
39.98
13.48
50.87%
HK:6699
Angelalign Technology Inc.
87.50
39.49
82.25%
HK:6929
OrbusNeich Medical Group Holdings Limited
3.85
0.23
6.35%
Shandong Weigao Group Medical Polymer Co Corporate Events
Weigao Medical Polymer Calls 2026 EGM to Approve Key Transaction and Non-Competition Agreements
Jan 26, 2026
Shandong Weigao Group Medical Polymer Company Limited has convened its first extraordinary general meeting of 2026 for 12 February in Weihai, Shandong, seeking shareholder approval for a series of transaction documents, including a sale and purcha...
Shandong Weigao Boosts Control of Blood Purification Arm in RMB8.5 Billion Asset Injection
Jan 5, 2026
Shandong Weigao Group Medical Polymer Company Limited has entered into a supplemental sale and purchase agreement with related parties to finalise the terms of transferring 100% equity interest in its non-wholly-owned subsidiary WEGO Prefills to W...
Weigao Medical Polymer Wins Shareholder Backing for Framework Deals, Director Reappointment and Company Restructuring
Dec 19, 2025
Shandong Weigao Group Medical Polymer Company Limited announced that its extraordinary general meeting held on 19 December 2025 approved all resolutions by poll, including framework agreements for purchases and logistic support services, the reapp...
Shandong Weigao Group Postpones EGM and Alters Book Closure Dates
Dec 2, 2025
Shandong Weigao Group Medical Polymer Company Limited has announced the postponement of its Extraordinary General Meeting (EGM) originally scheduled for 17 December 2025, now rescheduled to 19 December 2025 due to work arrangement coordination. Th...
Shandong Weigao Group Announces Extraordinary General Meeting for Key Resolutions
Dec 2, 2025
Shandong Weigao Group Medical Polymer Company Limited has announced an extraordinary general meeting to be held on December 17, 2025, to discuss and approve several key resolutions. These include the approval of the Purchase Framework Agreement an...
Shandong Weigao Group Renews Continuing Connected Transactions
Nov 28, 2025
Shandong Weigao Group Medical Polymer Company Limited has announced the renewal of its existing continuing connected transactions through Supplemental Agreements with Weigao Holding and its subsidiaries. These agreements involve revising the annua...
Shandong Weigao Forms Joint Venture to Expand in Indonesian Market
Nov 10, 2025
Shandong Weigao Group Medical Polymer Company Limited has announced the formation of a joint venture with PT Oneject Indonesia, named Oneject Wego Medical, to manufacture and sell medical consumables in Indonesia. This strategic move aims to tap i...
Shandong Weigao Group Reports Q3 Revenue Growth Amid Segment Challenges
Nov 3, 2025
Shandong Weigao Group Medical Polymer Company Limited reported a 2.6% year-on-year revenue increase for the third quarter, reaching approximately RMB3.26 billion. The orthopedic, interventional, and blood management segments saw significant growth...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.